Pharma & Biotech Global Week in Review 20 June 2012 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.


Highlights this week included:

Parties and amici file briefs in Myriad case (Patent Docs) (Holman’s Biotech Blog) (Holman’s Biotech Blog) (Holman’s Biotech Blog) (Holman’s Biotech Blog) (Holman’s Biotech Blog) (KEI) (PharmaPatents)


Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.



BIO takes stock: how global biotechnology benefits from intellectual property rights (Patent Baristas)

BIO 2012 day 1: China, IP and saving the world (Patent Baristas)

BIO 2012 day 2: Justices ponder hot tubbing (Patent Baristas)

BIO 2012: From bench to bendside in a bioeconomy (BIOtechNOW)

BIO 2012: Prior user rights and trade secrets (BIOtechNOW)

Docs at BIO: IP challenges to personalized medicine & diagnostics (Patent Docs)

BIO report on IP rights in developing countries (Patent Baristas)

Patent expirations put over $290 billion in Rx sales at risk (Patent Baristas)

Thomson Reuters finds increase in new research for ‘neglected’ tropical diseases (IP Solutions Blog)

Australia: Gene patenting called into question again (Patent Docs)

EU: Of propagation and prerogatives: IP litigation goes to seed – AG Jaaskinen delivers opinion in Case C-59/11 Raiffeisen Waren-Zentrale Rhein-Main eG v Saatgut-Treuhandverwaltungs GmbH (IPKat)

EU: Plant patentability questions deepen in EPO tomato patent case (IP Watch)

UK: EWHC (Pat) Antimicrobial wound dressings patent survives: Smith & Nephew v Convatec Technologies (IPKat)

US: Parties and amici file briefs in Myriad case (Patent Docs) (Holman’s Biotech Blog) (Holman’s Biotech Blog) (Holman’s Biotech Blog) (Holman’s Biotech Blog) (Holman’s Biotech Blog) (KEI)

US: Eli Lilly suggest bright-line rule in Myriad amicus brief (PharmaPatents)

US: 23 industrial, environmental, food and agricultural biotech companies send letter on Myriad case to Attorney General and Solicitor General (Patent Docs) (BIOtechNOW)

US: CAFC declines invitation to reconsider standing question in Myriad case (Patent Docs)

US: USPTO report on genetic testing delayed (Patent Docs)

US: “Bring out your dead” says OGD in a pre-GDUFA house cleaning move as the agency prepares for ANDAgeddon (FDA Law Blog)

US: When can’t a “listed drug” serve as a reference product for a 505(b)(2) application? (FDA Law Blog)

US: The language in S. 3187, calling for National Academies evaluation of Medical Innovation inducement prizes (KEI)

US: Recent developments in patentability: Prometheus and Myriad (BIOtechNOW)

US: Prometheus fails to steal fire from the gods (JIPLP)



Abilify (Aripiprazole) – US: CAFC on the U.S. doctrine of obviousness-type double patenting: Otsuka v Sandoz (Kluwer Patent Blog)

Cosopt (Timolol, Dorzolamide) – Netherlands: Court of Appeals confirms revocation of coformulation patent: Merck Sharp & Dohme v Sandoz (Kluwer Patent Blog)

Feminet (Desogestrel, Ethinyl estradiol) – Israel: Purple concept rejected – No unjust enrichment and no passing off: Dexon v Agis Trade Agency and Bayer Schering Pharma (The IP Factor)

Mevacor (Lovastatin) – Canada: SCC denies leave to hear s 8 case: Merck & Co v Apotex (Beeser Ramamoorthy)

Norvir (Ritonavir) – US: Reexamination requests against Abbott Labs’ HIV drug patents among those filed week of June 11, 2012 (WDHA)

Prezista (Darunavir) – US: Janssen Products files patent infringement suit against Hetero Drug and others in response to Para IV challenge (Patent Docs)

Singular (Montelukast) – UK: Pharmaceutical patent infringement and the specific mechanism – Merck Canada Inc and Merck Sharp & Dohme Ltd v Sigma Pharmaceuticals Plc [2012] EWPCC18 (Kluwer Patent Blog)

%d bloggers like this: